Oral GLP-1 Approaches Commercial Inflection by 2028 GLP-1 Weight Loss Drug Market Revenue Share, CAGR, and Primary Drivers by Route 2026 Subcutaneous injectable administration commands 81.7% GLP-1 market revenue share in 2026 as the weekly autoinjector format delivers clinical efficacy, dose consistency, and patient convenience superior to daily injectable alternatives
Sources MHRA smashes major illicit weight loss medicine production facility in record seizure, MHRA [accessed 29 October 2025] Mounjaro KwikPen 2.5mg solution for injection in pre-filled pen, emc [accessed 29 October 2025] Once-Weekly Semaglutide in Adults with Overweight or Obesity, The New England Journal of Medicine (NEJM) [accessed 29 October 2025] Tirzepatide Once Weekly for the Treatment of Obesity, NEJM [accessed 29 October 2025] TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial, NEJM[accessed 29 October 2025] Patient Reviews Related Weight Loss Treatments Further Reading on Weight Loss Do Appetite Suppressants Work
Cardiac Monitoring: Transient increases in heart rate have been noted in trials, likely linked to glucagon receptor activity
What is Retatrutide used for
GLP-1 Receptor Agonist Market Companies The competitive landscape of the GLP-1 receptor agonist industry includes Boehringer Ingelheim International GmbH Eli Lilly and Company Sanofi Novo-Nordisk A/S AstraZeneca Pfizer.Inc Amgen, Inc
Research from 2021 has found that, in conjunction with appropriate lifestyle habits, they can help people lose a significant amount of weight or maintain weight loss
